Dapagliflozin

CAS 461432-26-8 35 current recordsSmall Molecule

Who holds supplier records for Dapagliflozin? 35 organisations hold a current record for Dapagliflozin: an active US FDA Type II Drug Master File. Recorded organisation countries for current records: India (24), China (8) and Poland (1); not recorded for 2.

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Dapagliflozin: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/dapagliflozin

Reading the evidence

  • 35 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    24 of the 33 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 21 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Dapagliflozin expires 1 Oct 2041. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (35)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Dapagliflozin. Country is the organisation's recorded country, not necessarily the manufacturing site.

India24China8Poland1Country not recorded for 2
Need Dapagliflozin sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (32 listed products contain Dapagliflozin). The latest listed patent expires 1 Oct 2041. The latest listed exclusivity runs to 12 Dec 2027. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Dapagliflozin is a sodium-glucose cotransporter 2 inhibitor used to manage type 2 diabetes mellitus. It helps improve glycemic control and has cardiovascular benefits.

Chemical identity

IUPAC name
(2S,3R,4R,5S,6R)-2-[4-chloro-3-[(4-ethoxyphenyl)methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
Canonical SMILES
CCOC1=CC=C(C=C1)CC2=C(C=CC(=C2)[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)Cl
InChIKey
JVHXJTBJCFBINQ-ADAARDCZSA-N
Synonyms
bms-512148, br1019 component dapagliflozin, dapagliflozin component qternmet, lyn-045, qternmet component dapaglifozin, qternmet xr component dapagliflozin

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Sodium-Glucose Cotransporter 2 Inhibitor
Mechanism of action
Sodium-Glucose Transporter 2 Inhibitors

Therapeutic areas

DiabetesCardiovascularMetabolic Disorders

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Dapagliflozin?

35 organisations hold an active US FDA Type II Drug Master File or a CEP for Dapagliflozin: AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (India), MSN Laboratories Private Limited (India), Zhejiang Jingsheng Pharmaceutical Co., Ltd. (China), Alembic Pharmaceuticals Limited (India), ALIVUS LIFE SCIENCES LTD (India), AMI LIFESCIENCES PRIVATE LTD (India), APITORIA PHARMA PRIVATE LTD (India) and AZICO BIOPHORE INDIA PVT LTD (India), and 27 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Dapagliflozin Drug Master Files are active?

AMOLI ORGANICS (A DIVISION OF UMEDICA LABORATORIES PVT LTD) (DMF 40237, 42486), MSN Laboratories Private Limited (DMF 43828, 30299), Zhejiang Jingsheng Pharmaceutical Co., Ltd. (DMF 39656, 41471), Alembic Pharmaceuticals Limited (DMF 32005), ALIVUS LIFE SCIENCES LTD (DMF 31284), AMI LIFESCIENCES PRIVATE LTD (DMF 38009), APITORIA PHARMA PRIVATE LTD (DMF 31841) and AZICO BIOPHORE INDIA PVT LTD (DMF 38370) and 27 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

Does the FDA Orange Book list patents for products containing Dapagliflozin?

Yes. The latest patent listed for an approved US product containing Dapagliflozin expires 1 Oct 2041, across 32 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Dapagliflozin supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Dapagliflozin?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.